Immune Checkpoint Inhibition in Esophagogastric Cancers
An article in Targeted Oncology reviews the treatment strategy that’s changing the treatment landscape for gastric cancer: immunotherapy.
FDA Approvals in RCC and CML, Priority Review Designations in NSCLC and RCC, and More
The European Union’s Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Herzuma, a trastuzumab biosimilar, for treating HER2-positive... Read More
BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers
New research in Human Pathology finds BRCA1 and BRCA2 can be used as clinicopathological biomarkers to assess the prognosis of gastric cancer.
Early Palliative Care Improves QOL for Lung and GI Cancer Patients
A new study in the Journal of Clinical Oncology finds early palliative care leads to enhanced coping strategies and improved quality of... Read More
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer
A new phase 2 study in Japan and South Korea will evaluate the efficacy and safety of DS-8201 in ER2-expressing gastric cancer.
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden
A nationwide cohort study in Sweden suggests long-term proton pump inhibitor (PPI) use might be an independent risk factor for gastric cancer,... Read More
Increased Oral Pathogens and Decreased Bacterial Diversity Predict Precancerous Lesions of Stomach Cancer
New research out of NYU shows an increase in pathogens associated with periodontal disease and a decrease in bacterial diversity in the... Read More
Expression of annexin II in gastric carcinoma and its role in gastric cancer metastasis.
A new study finds high expression of annexin II could promote the invasion and metastasis of gastric cancer.
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
A new study in GUT found the long-term use of proton pump inhibitors was still associated with an increased gastric cancer risk... Read More
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
While a phase III study did not find a significant improvement in overall survival of Asian patients with advanced #StomachCancer treated with... Read More
